For kidney transplant (KT) recipients with mild COVID-19 (including the Omnicron variant), neutralizing monoclonal antibody therapy (mAb)was linked with positive outcomes, according to a study published in Kidney Medicine. In a single-center retrospective investigation, researchers evaluated consecutive KT recipients treated with mAb for COVID-19 between June 10, 2021 and January 14, 2022, among whom 83% were vaccinated with at least two doses before infection; 77% had demonstrated a vaccineinduced humoral response. Participants received either casirivimab-imdevimab (34%) or sotrovimab (66%) at a median of 2 days after symptoms appeared. No side effects were noted, except for one mild adverse reaction during casirivimab-imdevimab infusion. At admission, median viral load was at 2,110,027 (ranges 1000- 153,798,962) copies/mL; at 7 days after mAb infusion, median viral loads were 1,000 (ranges 0-10,000,000) copies/mL. For those KT recipients with the Omicron variant, the median viral loads at admission and day 7 were 752,789 (ranges 4000-12,859,300) copies/mL and 1,353 (ranges 0-1,211,163) copies/mL, respectively. No patients were admitted to the ICU or died.
